Job title: CEO & Director
Jeffrey M. Ostrove, Ph.D. is the CEO of Locana, an RNA targeting gene therapy company developing treatments for a variety of neuromuscular and genetic diseases. Prior to Locana, he was CEO of AbVitro Inc., a therapeutic target discovery company which he sold to Juno Therapeutics. Prior to AbVitro, Dr. Ostrove was the president and CEO of Ceregene, Inc., a clinical stage company developing treatments for Alzheimer’s and Parkinson’s disease. Ceregene sold to Sangamo. Prior to Ceregene, Dr. Ostrove was COO of NeuroVir, and instrumental in its merger with Medigene. Preceding NeuroVir (Medigene), Dr. Ostrove served as SVP and chief scientist of MAGENTA of Rockville, Maryland, a CDMO he founded while at BioReliance, Inc. where he was VP of scientific development. Dr. Ostrove served on the staff of the NIAID at the NIH. Dr. Ostrove holds a Ph.D. in molecular biology from the University of Florida College of Medicine and completed his post-doc at The Johns Hopkins University School of Medicine. Dr. Ostrove is also a past Board member of the Biotechnology Innovation Organization (BIO).
Harnessing RNA-binding proteins to develop a portfolio of RNA-targeting gene therapies 10:10 am
– Developing CRISPR-based therapies that target and edit RNA – Exploring the strategy that could be used to destroy disease-causing RNA transcripts in conditions like myotonic dystrophy and amyotrophic lateral sclerosis – Looking beyond CRISPR for RNA-binding proteins that could be engineered for making RNA-editing therapiesRead more
day: Day Two